TY  - JOUR
TI  - Benefits and Toxicity of Taxane Addition to PlatinumFluoropyrimidine Combination in Gastric Cancer Patients with Peritoneal Metastasis
AB  - Objective: In advanced gastric cancer (AGC), peritoneal metastasis (PM) is associated with poor prognosis and worse performance status (PS), which makes chemotherapy administration difficult. However, PM can present with many different clinical pictures. The aim of this study was to investigate the benefits and toxicity of taxane addition to platinum-fluoropyrimidine combination in clinically poor (CPPG) and good prognostic groups (CGPG) of AGC patients with PM. Material and Methods: A total of 172 AGC patients with PM who were treated with taxane plus platinum plus fluoropyrimidine (TPF) or platinum plus fluoropyrimidine (PF) were included in the study. The patients with massive ascites or PS 2-3 or inadequate oral intake were included in the CPPG group, while those with an absence of these clinical factors were included in the CGPG group. The efficacy and toxicity of dose intensity on survival were evaluated separately for each group using the Kaplan-Meier method. Results: At the baseline, 16.9% of all patients had massive ascites, 30.2% had PS of ≥2, and 33.7% had inadequate oral intake. Accordingly, 50.6% of the patients were in CPPG. The overall survival times were found to be similar in patients treated with TPF as well as those treated with PF. Moreover, the addition of taxane treatment did not have any effect on either the poor prognostic group or the good prognostic group. However, as the dose intensity was increased, the grade 3/4 toxicity, dose delay, and reduction rates also increased. Conclusion: Addition of taxane to PF did not contribute to survival in AGC patients with peritoneal metastasis, independent of the clinical prognostic group
AU  - Ozdemir, Nuriye
AU  - AKTAS, GOKMEN
AU  - Yalcintas arslan, Ulku
AU  - Akkuş, Gülsüm
AU  - YESIL ÇINKIR, HAVVA
AU  - Ozet, Ahmet
AU  - dirikoç, merve
AU  - kus, tulay
AU  - sutcuoglu, osman
AU  - Köse, Fatih
DO  - 10.37047/jos.2022-90537
PY  - 2022
JO  - Journal of oncological sciences
VL  - 8
IS  - 3
SN  - 2651-4532
SP  - 127
EP  - 134
DB  - TRDizin
UR  - http://search/yayin/detay/1169531
ER  -